Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy.
| Autor: | Doberstein SK; Nektar Therapeutics, San Francisco, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on biological therapy [Expert Opin Biol Ther] 2019 Dec; Vol. 19 (12), pp. 1223-1228. Date of Electronic Publication: 2019 Oct 31. |
| DOI: | 10.1080/14712598.2019.1685489 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|